237690 — ST Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapHigh Flyer

Market Cap
KR₩3tn
Enterprise Value
KR₩3tn
Revenue
KR₩332bn

Annual income statement for ST Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	165,642	249,322	284,992	273,751	331,681
Cost of Revenue
Gross Profit	57,743	88,932	112,115	96,163	136,203
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	160,064	231,469	251,533	246,201	276,707
Operating Profit	5,578	17,852	33,459	27,550	54,974
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,260	19,237	23,354	42,747	58,723
Provision for Income Taxes
Net Income After Taxes	3,377	17,516	17,523	32,464	54,562
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,312	18,000	19,581	34,712	54,992
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	3,312	18,000	19,581	34,712	57,652
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	305	988	1,043	1,842	2,701
Dividends per Share